CAS-backed AI processor provider Cambricon, valued at $2.5bn in 2018, floated on Shanghai's Star Market.
Baylor College spinout AlloVir has filed to raise up to $100m in an offering that will support the clinical development of a treatment for viral diseases.
UC Berkeley and UC San Francisco-linked small molecule cancer drug developer Nurix Therapeutics has filed for an IPO on the Nasdaq Global Market.
Novo and Sanofi are among the investors that could exit Yale's mineralisation disease therapy developer, which has filed to raise up to $86.3m.
University of Tübingen’s immuno-oncology spinout Immatics has undertaken a reverse merger with special purpose acquisition company Arya Sciences to list in the US.
QuantumCTek has filed for a $102m initial public offering, more than a decade after being spun out of University of Science and Technology of China.
The UC Berkeley-linked cell biology technology provider has raised about $215m in venture funding.
Facit exited McMaster University's cancer radiotherapy spinout in an upsized initial public offering after $158m in funding.
University of Kent's UltraSoc Technologies, which provides integrated circuit safety technologies, has agreed to an acquisition by Siemens.
Oncology treatment developer Relay Therapeutics is advancing research from several universities and has now filed for a $200m IPO.